508 related articles for article (PubMed ID: 28654204)
21. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
22. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
Bissonette EA; Fulmer BR; Petroni GR; Moul JW; Theodorescu D
J Urol; 2001 Oct; 166(4):1328-31; discussion 1331-2. PubMed ID: 11547067
[TBL] [Abstract][Full Text] [Related]
23. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.
Amling CL; Riffenburgh RH; Sun L; Moul JW; Lance RS; Kusuda L; Sexton WJ; Soderdahl DW; Donahue TF; Foley JP; Chung AK; McLeod DG
J Clin Oncol; 2004 Feb; 22(3):439-45. PubMed ID: 14691120
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
25. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Chu DI; Moreira DM; Gerber L; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
Cancer; 2012 Oct; 118(20):4999-5007. PubMed ID: 22415377
[TBL] [Abstract][Full Text] [Related]
26. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
[TBL] [Abstract][Full Text] [Related]
27. Race, tumor location, and disease progression among low-risk prostate cancer patients.
Mygatt JG; Cullen J; Streicher SA; Kuo HC; Chen Y; Young D; Gesztes W; Williams G; Conti G; Porter C; Stroup SP; Rice KR; Rosner IL; Burke A; Sesterhenn I
Cancer Med; 2020 Mar; 9(6):2235-2242. PubMed ID: 31965751
[TBL] [Abstract][Full Text] [Related]
28. Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
Wilkins LJ; Tosoian JJ; Reichard CA; Sundi D; Ranasinghe W; Alam R; Schwen Z; Reddy C; Allaf M; Davis JW; Chapin BF; Ross AE; Klein EA; Nyame YA
Cancer; 2021 May; 127(9):1425-1431. PubMed ID: 33721334
[TBL] [Abstract][Full Text] [Related]
29. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.
Jayachandran J; Bañez LL; Aronson WJ; Terris MK; Presti JC; Amling CL; Kane CJ; Freedland SJ;
Cancer; 2009 Nov; 115(22):5263-71. PubMed ID: 19670453
[TBL] [Abstract][Full Text] [Related]
30. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
31. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
[TBL] [Abstract][Full Text] [Related]
32. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
Schulman AA; Howard LE; Tay KJ; Tsivian E; Sze C; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ; Polascik TJ
Cancer; 2017 Nov; 123(21):4122-4129. PubMed ID: 28662291
[TBL] [Abstract][Full Text] [Related]
33. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy.
Shah SR; Freedland SJ; Aronson WJ; Kane CJ; Presti JC; Amling CL; Terris MK
BJU Int; 2009 May; 103(9):1168-72. PubMed ID: 19298411
[TBL] [Abstract][Full Text] [Related]
34. Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort.
Wadhwa H; Terris MK; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ; Abern MR
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):423-428. PubMed ID: 27698440
[TBL] [Abstract][Full Text] [Related]
35. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
36. Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.
Freedland SJ; Dorey F; Aronson WJ
Urology; 2000 Nov; 56(5):807-11. PubMed ID: 11068307
[TBL] [Abstract][Full Text] [Related]
37. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
38. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
40. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.
Cullen J; Young D; Chen Y; Degon M; Farrell J; Sedarsky J; Baptiste W; Rosen P; Tolstikov V; Kiebish M; Kagan J; Srivastava S; Kuo HC; Moncur JT; Rosner IL; Narain N; Akmaev V; Petrovics G; Dobi A; McLeod DG; Srivastava S; Sesterhenn IA
Eur Urol Focus; 2018 Dec; 4(6):818-824. PubMed ID: 28753864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
